Evidence map›Paper›PMID 33397903›Full record

ArticleNature communications2021

Analysis of SARS-CoV-2 antibodies in COVID-19 convalescent blood using a coronavirus antigen microarray.

Rafael R de Assis, Aarti Jain, Rie Nakajima, Algis Jasinskas, Jiin Felgner, Joshua M Obiero, Philip J Norris, Mars Stone, Graham Simmons, Anil Bagri and 17 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 111 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
111citing papers in PubMed, 4 pooled it
10.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

111 citing papers in PubMed, 4 syntheses or guidelines pooled it, 195 citations in OpenAlex.

  1. Convalescent plasma for people with COVID-19: a living systematic review.The Cochrane database of systematic reviews · 2023
    Pooled it
  2. Convalescent plasma for people with COVID-19: a living systematic review.The Cochrane database of systematic reviews · 2023
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Article
  7. ACS pharmacology & translational science · 2025
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Peptide Microarrays for Flavivirus Diagnosis.Methods in molecular biology (Clifton, N.J.) · 2023
    Article
  19. Aptamer-Based Strategies to Address Challenges in COVID-19 Diagnosis and Treatments.Interdisciplinary perspectives on infectious diseases · 2023
    Review
  20. Article

51 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors at 8 institutions in 2 countries.

Rafael R de AssisDepartment of Physiology and Biophysics, School of Medicine, University of California, Irvine, CA, USA.
Aarti JainDepartment of Physiology and Biophysics, School of Medicine, University of California, Irvine, CA, USA.
Rie NakajimaDepartment of Physiology and Biophysics, School of Medicine, University of California, Irvine, CA, USA.
Algis JasinskasDepartment of Physiology and Biophysics, School of Medicine, University of California, Irvine, CA, USA.
Jiin FelgnerDepartment of Physiology and Biophysics, School of Medicine, University of California, Irvine, CA, USA.
Joshua M ObieroDepartment of Physiology and Biophysics, School of Medicine, University of California, Irvine, CA, USA.ORCID 0000-0001-9741-512X
Philip J NorrisVitalant Research Institute, San Francisco, CA, USA.
Mars StoneVitalant Research Institute, San Francisco, CA, USA.
Graham SimmonsVitalant Research Institute, San Francisco, CA, USA.
Anil BagriCerus Corporation, Concord, CA, USA.
Johannes IrschCerus Corporation, Concord, CA, USA.
Martin SchreiberDepartment of Surgery, Oregon Health & Science University, Portland, OR, USA.
Andreas BuserDivision of Infectious Diseases & Hospital Epidemiology, University Hospital Basel, University of Basel, Basel, Switzerland.ORCID 0000-0002-7942-6746
Andreas HolbroDepartment of Surgery, Oregon Health & Science University, Portland, OR, USA.
Manuel BattegayDivision of Infectious Diseases & Hospital Epidemiology, University Hospital Basel, University of Basel, Basel, Switzerland.
Philip HosimerOrtho Clinical Diagnostics, Rochester, NY, USA.
Charles NoesenOrtho Clinical Diagnostics, Rochester, NY, USA.
Oluwasanmi AdenaiyeInstitute for Applied Environmental Health, School of Public Health, University of Maryland, College Park, MD, USA.
Sheldon TaiInstitute for Applied Environmental Health, School of Public Health, University of Maryland, College Park, MD, USA.
Filbert HongInstitute for Applied Environmental Health, School of Public Health, University of Maryland, College Park, MD, USA.
Donald K MiltonInstitute for Applied Environmental Health, School of Public Health, University of Maryland, College Park, MD, USA.ORCID 0000-0002-0550-7834
D Huw DaviesDepartment of Physiology and Biophysics, School of Medicine, University of California, Irvine, CA, USA.
Paul ContestableOrtho Clinical Diagnostics, Rochester, NY, USA.
Laurence M CorashCerus Corporation, Concord, CA, USA.
Michael P BuschVitalant Research Institute, San Francisco, CA, USA.ORCID 0000-0002-1446-125X
Philip L FelgnerDepartment of Physiology and Biophysics, School of Medicine, University of California, Irvine, CA, USA.ORCID 0000-0002-4117-8505
Saahir KhanDivision of Infectious Diseases, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. saahirkh@usc.edu.ORCID 0000-0001-6732-768X
University of California, Irvine · USUniversity of California, San Francisco · USUniversity of Maryland, College Park · USCerus (United States) · USOrtho Clinical Diagnostics (United States) · USOregon Health & Science University · USUniversity of Basel · CHUniversity of Southern California · US

Funding

Institutional Career Development CoreKL2TR001416 · NCATS · UNIVERSITY OF CALIFORNIA-IRVINE · PI CAIOZZO, VINCENT JAMES, DEMETRIOU, MICHAEL · 2015 to 2023
$5.6M
NCATS NIH HHS KL2 TR001416
6 · The paper itself

Abstract

The current practice for diagnosis of COVID-19, based on SARS-CoV-2 PCR testing of pharyngeal or respiratory specimens in a symptomatic patient at high epidemiologic risk, likely underestimates the true prevalence of infection. Serologic methods can more accurately estimate the disease burden by detecting infections missed by the limited testing performed to date. Here, we describe the validation of a coronavirus antigen microarray containing immunologically significant antigens from SARS-CoV-2, in addition to SARS-CoV, MERS-CoV, common human coronavirus strains, and other common respiratory viruses. A comparison of antibody profiles detected on the array from control sera collected prior to the SARS-CoV-2 pandemic versus convalescent blood specimens from virologically confirmed COVID-19 cases demonstrates near complete discrimination of these two groups, with improved performance from use of antigen combinations that include both spike protein and nucleoprotein. This array can be used as a diagnostic tool, as an epidemiologic tool to more accurately estimate the disease burden of COVID-19, and as a research tool to correlate antibody responses with clinical outcomes.

Indexed as

Antibodies, ViralAntigens, ViralCOVID-19COVID-19 TestingHumansImmunoglobulin GImmunoglobulin MMicroarray AnalysisMiddle East Respiratory Syndrome CoronavirusNeutralization TestsSARS-CoV-2Severe acute respiratory syndrome-related coronavirusSpike Glycoprotein, CoronavirusAntibodies, ViralAntigens, ViralImmunoglobulin GImmunoglobulin MSpike Glycoprotein, Coronavirus

Identifiers

PMID33397903
PMCPMC7782488
OpenAlexW3118781919

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.